Get the Weekly Intelligence Brief — top committee picks every Sunday.

ATR vs PRAX

AptarGroup vs Praxis Precision Medicines, Inc. — AI-powered side-by-side comparison
ATR
AptarGroup
69
Buy
VS
PRAX
Praxis Precision Medicines, Inc.
59
Watch
MetricATRPRAX
AI Score 69 59
Price $134.62 $370.53
P/E Ratio 24.06× -28.62×
ROE 14.7% -34.5%
Revenue Growth YoY
Gross Margin 28.3% 0.0%
Debt / Equity 0.54× 0.00×
Dividend Yield 1.4% 0.0%
RSI (14) 48.2 74.4
Beta 0.382 2.776
Expected Upside +1.6%

AI Committee View

Current Innellis committee reasoning for ATR versus PRAX.
ATR leads by 10 points.

ATR scores 69/100 (Buy) versus PRAX at 59/100 (Watch).

ATR Committee View
75% agreement
4 analysts

The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is macd histogram negative -- bearish momentum. The committee is constructive but not yet at full conviction.

Bull Case
  • 5 consecutive earnings beats -- consistent execution — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
  • MACD histogram negative -- bearish momentum — Technical
PRAX Committee View
60% agreement
5 analysts

Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.

Bull Case
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
  • Price-to-book of 8.4x prices in significant intangible value — Value
  • ROE of only -43.0% -- cheap may mean cheap for a reason — Value
  • RSI at 74 is in overbought territory — Technical
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
ATR Full Analysis PRAX Full Analysis